Диссертация (1139774), страница 27
Текст из файла (страница 27)
- V. 15. - P. 31229. Sanger T.M., Lieberman J.A., Tohen M., Grundy S., Beasley C.J., Tollefson G.D.Olanzapine versus haloperidol treatment in first-episode psychosis // American Journalof Psychiatry. - 1999. - V. 156(1). - P. 79-87.230. Scarpini F., Cappellone R., Auteri A., Puccetti L. Role of genetic factors in statinsside-effects // Cardiovascular & Hematological Disorders Drug Targets.
- 2012. - V.12(1). - P. 35-43.231. Schillevoort I., de Boer A., van der Weide J., Steijns L.S., Roos R.A., JansenP.A., Leufkens H.G. Antipsychotic-induced extrapyramidal syndromes and cytochromeP450 2D6 genotype: a case−control study // Pharmacogenetics. - 2002. - V. 12. - P. 23540.232. Schorr S.G., Brouwers J.R., Taxis K. If drugs are not taken-how differentantipsychotics influence compliance of schizophrenic patients [in German] //Fortschritte Der Neurologie-Psychiatrie Journal. - 2007. - V.
75. - P. 473-7.233. Shah R.R. Can pharmacogenetics help rescue drugs withdrawn from the market?// Pharmacogenomics. - 2006. - V. 7(6). - P. 889-908.234. Shared care protocol Thioridazine (PDF). NHS Lothian Joint Formulary. 2012.235. Shedlack K.J., Soldato-Couture C., Swanson C.L. Rapidly progressive tardivedyskinesia in AIDS // Biological Psychiatry. - 1994. - V. 35(2). - P. 147-8.236.
Shuman M.D., Trigoboff E., Demler T.L., Opler L.A. Exploring the potentialeffect of polypharmacy on the hematologic profiles of clozapine patients // Journal ofPsychiatric Practice. - 2014. - V. 20(1). - P. 50-8.237. Sistonen J., Sajantila A., Lao O., Corander J., Barbujani G., Fuselli S. CYP2D6worldwide genetic variation shows high frequency of altered activity variants and nocontinental structure // Pharmacogenetics and Genomics.
- 2007. - V. 17(2). - P. 93-101.238. Spina E., Ancione M., Di Rosa A.E., Meduri M. Polymorphic debrisoquineoxidation and acute neuroleptic-induced adverse effects // European journal of clinicalpharmacology. - 1992. - V. 42(3). - P. 347-8.159239. Stahl S.M., Mignon L., Meyer J.M. Which comes first: atypical antipsychotictreatment or cardiometabolic risk? // Acta Psychiatrica Scandinavica. - 2009.
V. 119. P. 171–9.240. Strange P.G. Antipsychotic drug action: antagonism, inverse agonism or partialagonism // Trends in Pharmacological Sciences. - 2008. - V. 29. - P. 314-21.241. Strawn J.R. Keck Jr. P.E., Caroff S.N. Neuroleptic Malignant Syndrome //American Journal of Psychiatry.
- 2007. - V. 164. - P.870-6.242. Strickland T.L., Stein R., Lin K.M., Risby E., Fong R. The pharmacologictreatment of anxiety and depression in African Americans. Considerations for thegeneral practitioner // Archives of Family Medicine.
- 1997. - V. 6(4). - P. 371-5.243. Svarstad B.L., Shireman T.I., Sweeney J.K. Using drug claims data to assess therelationship of medication adherence with hospitalization and costs // PsychiatricServices. - 2001. - V. 52(6). - P. 805-11.244. Sweileh W.M, Odeh J.B., Zyoud S.H., Sawalha A.F., Ihbeasheh M.S.Conformance to schizophrenia treatment guidelines in North West-Bank, Palestine:focus on antipsychotic dosing and polytherapy // BMC Psychiatry. 2013. - V. 13. - P.179.245.
Swen J.J., Nijenhuis M., de Boer A., Grandia L., Maitland-van der Zee A.H.,Mulder H., Rongen G.A., van Schaik R.H., Schalekamp T., Touw D.J., van der WeideJ., Wilffert B., Deneer V.H., Guchelaar H.J. Pharmacogenetics: from bench to byte-anupdate of guidelines Review // Clinical Pharmacology & Therapeutics. - 2011. - V.89(5).
- P. 662-73.246. Syu A., Ishiguro H., Inada T., Horiuchi Y., Tanaka S., Ishikawa M., Arai M.,Itokawa M., Niizato K., Iritani S., Ozaki N., Takahashi M., Kakita A., Takahashi H.,Nawa H., Keino-Masu K., Arikawa-Hirasawa E., Arinami T. Association of the HSPG2gene with neuroleptic-induced tardive dyskinesia // Neuropsychopharmacology. - 2010.- V. 35(5). - P. 1155-64.247. Tamminga W.J., Wemer J., Oosterhuis B., de Boer A., Vranckx S., Drenth B.F.,de Zeeuw R.A., de Leij L.F., Jonkman J.H. Polymorphic drug metabolism (CYP2D6)160and utilisation of psychotropic drugs in hospitalised psychiatric patients: a retrospectivestudy // European Journal of Clinical Pharmacology. - 2003. V. 59.
- P. 57−64.248. Tang H., Quertermous T., Rodriguez B., Kardia S.L., Zhu X., Brown A., PankowJ.S., Province M.A., Hunt S.C., Boerwinkle E., Schork N.J., Risch N.J. GeneticStructure, Self-Identified Race/Ethnicity, and Confounding in Case-Control AssociationStudies // American Journal of Human Genetics. - 2005. - V.
76. - P. 268-75.249. Tapp A., Wood A.E., Secrest L., Erdmann J., Cubberley L., Kilzieh N.Combination Antipsychotic Therapy in Clinical Practice // Psychiatric Services. - 2003.- V. 54(1). - P. 55-9.250. Taylor D.M.S., Mace S., Whiskey E. Co-prescribing of atypical and typicalantipsychotics - prescribing sequence and documented outcome // Psychiatric Bulletin. 2002.
- V. 26. - P. 170-2.251. Taylor M. Antipsychotic Side-Effect Rating Scales in Schizophrenia. In: Keefe. R(ed.) Guide to Assessment Scales in Schizophrenia. Berlin: 2012. Springer Healthcare.252. Teh L.K., Yusoff R., Hussein A., Isa M.N., Rahman A.R.A., Ismail R.Heterogeneity of the CYP2D6 gene among Malays in Malaysia // Journal of ClinicalPharmacy and Therapeutics. - 2001. - V. 26(3).
- P. 205-11.253. The Human Cytochrome P450 (CYP) Allele Nomenclature Database. URL:http://www.cypalleles.ki.se/cyp2d6.htm. (дата обращения 07.06.2016).254. Tiihonen J., Suokas J.T., Suvisaari J.M., Haukka J., Korhonen P. Polypharmacywith antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia// Archives of General Psychiatry.
- V. 69(5). - P. 476-83.255. Tiwari A.K., Deshpande S.N., Rao A.R., Bhatia T., Lerer B., Nimgaonkar V.L.,Thelma B.K. Genetic susceptibility to tardive dyskinesia in chronic schizophreniasubjects: III. Lack of association of CYP3A4 and CYP2D6 gene polymorphisms //Schizophrenia Research. - 2005. - V. 75(1).
- P. 21-6.256. Toda M., Abi-Dargham A. Dopamine hypothesis of schizophrenia: making senseof it all // Current Psychiatry Reports. - 2007. - V. 9. - P. 329-36.257. Tsai H.T., Caroff S.N., Miller del D., McEvoy J., Lieberman J.A., North K.E.,Stroup T.S., Sullivan P.F. A candidate gene study of tardive dyskinesia in the CATIE161schizophrenia trial // American Journal of Medical Genetics Part B: NeuropsychiatricGenetics.
- 2010. - V. 153B(1). - P. 336-40.258. Tsai H.T., North K.E., West S.L., Poole C. The DRD3 rs6280 polymorphism andprevalence of tardive dyskinesia: a meta-analysis // American Journal of MedicalGenetics Part B: Neuropsychiatric Genetics. - 2010. - V. 153B(1).
- P. 57-66.259. Types of Medication Errors. The National Coordinating Council for MedicationError Reporting and Prevention. URL: http://www.nccmerp.org/types-medication-errors(дата обращения: 21.04.2017).260. U.S. Food and Drug Administration. Table of pharmacogenomic biomarkers indrug labels, 2013.
URL: https://www.fda.gov/Drugs/ScienceResearch/ucm572698.htm.(дата обращения 07.10.2017).261. URL: http://care.diabetesjournals.org/content/27/2/596.full (дата обращения15.06.2015).262. Vandereycken W., Kuyken K. Een analyse van advertenties voor psychofarmacain het Tijdschrift voor Psychiatrie [An analysis of advertisements for psychotropic drugsin the Dutch Journal of Psychiatry] // Tijdschrift voor Psychiatrie.
- 2009. - V. 51 (6). P. 407-411.263. Verdoux H., Tournier M., Bégaud B. Antipsychotic prescribing trends: a reviewof pharmaco-epidemiological studies // Acta Psychiatrica Scandinavica. - 2010. - V.121. - P. 4–10.264. Viikki M., Kampman O., Seppälä N., Mononen N., Lehtimäki T., Leinonen E.CYP1A2 polymorphism -1545C>T (rs2470890) is associated with increased side effectsto clozapine // BMC Psychiatry.
- 2014. - V. 14(2). - P. 50.265. Vivot A., Boutron I., Ravaud P., Porcher R. Guidance for pharmacogenomicbiomarker testing in labels of FDA-approved drugs // Genetics in Medicine. - 2015. - V.17(9). - P. 733-8.266. Wang J.S., Zhu H.J., Markowitz J.S., Donovan J.L., Devane C.L. Evaluation ofantipsychotic drugs as inhibitors of multidrugresistance transporte P-glycoprotein //Psychopharmacology. - 2006. - V. 187. - P. 415-23.162267. WHO Collaborating Centre for Drug Statistics Methodology, Guidelines for ATCclassification and DDD assignment 2013. 16th edition.
Oslo, 2012.268. Wirshing D.A., Boyd J.A., Meng L.R., Ballon J.S., Marder S.R., Wirshing W.C.The effects of novel antipsychotics on glucose and lipid levels // Journal of ClinicalPsychiatry. - 2002. - V. 63. - P. 856-65.269. Witchel H.J., Hancox J.C., Nutt D.J. Psychotropic drugs, cardiac arrhythmia, andsudden death // Journal of Clinical Psychopharmacology.
- 2003. - V. 23. - P. 58-77.270. Woods S.W., Morgenstern H., Saksa J.R. et al. Incidence of tardive dyskinesiawith atypical versus conventional antipsychotic medications: a prospective cohort study// Journal of Clinical Psychiatry. - 2010. - V. 71(4). - P. 463-74.271. WorldHealthOrganization(WHO).Mentalhttp://www.who.int/mental_health/management/schizophrenia/en/health,(дата2014.обращения10.02.2016).272. Wu C.-S., Lin Y.-J., Feng J.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
